Clinical Trial Update: Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing lumiliximab added to FCR versus FCR alone in relapsed chronic lymphocytic leukemia; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Fludarabine (Fludarabine)
• Lumiliximab (Lumiliximab)
• Rituximab (rituximab)

Snippet

Sponsor: Biogen | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: TERMINATED